Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02707861
Recruitment Status : Completed
First Posted : March 14, 2016
Last Update Posted : November 8, 2018
Information provided by (Responsible Party):
TaiMed Biologics Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2018
  Actual Study Completion Date : November 2018